
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 7)*

KODIAK SCIENCES INC.

(Name of Issuer)

Common Stock, \$0.0001 par value per share

(Title of Class of Securities)

50015M109

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 50015M109

Names of Reporting Persons

1 D. VICTOR PERLROTH, M.D.

Check the appropriate box if a member of a Group (see instructions)

- 2 (a)
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 UNITED STATES

	Sole Voting Power
5	6,504,427.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	5,977,427.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	6,504,427.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	9.9 %
12	Type of Reporting Person (See Instructions)
	IN

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

KODIAK SCIENCES INC.

Address of issuer's principal executive offices:

(b)

1250 PAGE MILL RD, PALO ALTO, CA, 94304.

Item 2.

Name of person filing:

(a)

D. Victor Perloth, M.D.

Address or principal business office or, if none, residence:

(b)

c/o Kodiak Sciences Inc. 1250 Page Mill Road Palo Alto, CA 94304

Citizenship:

(c)

United States

Title of class of securities:

(d)

Common Stock, \$0.0001 par value per share

CUSIP No.:

(e)

50015M109

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

- (a) Row 9 of the Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by the Reporting Person and is incorporated by reference. Row 9 includes (i) 2,095,538 shares of Common Stock held directly by Dr. Perloth, (ii) 3,809,389 shares of Common Stock subject to options held by Dr. Perloth that are immediately exercisable or exercisable within 60 days of December 31, 2025, including 658,919 shares of which are unvested and subject to an Issuer right of repurchase as of March 1, 2026, (iii) 72,500 shares of Common Stock held by the Perloth Family Foundation U/A DTD 12/27/2006 for which Dr. Perloth is a trustee, and (iv) 527,000 shares of Common Stock as to which Dr. Perloth has sole voting power and no investment power pursuant to a voting agreement and proxy.

Percent of class:

- (b) Row 11 of the Reporting Person's cover page to this Schedule 13G sets forth the percentage of the shares of securities of the Issuer beneficially owned by the Reporting Person as of December 31, 2025, and is incorporated by reference. The percentage set forth in Row 11 is based upon 61,758,454 shares of Common Stock outstanding as of December 31, 2025. %

- (c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

6,504,427

(ii) Shared power to vote or to direct the vote:

0

(iii) Sole power to dispose or to direct the disposition of:

5,977,427

(iv) Shared power to dispose or to direct the disposition of:

0

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

D. VICTOR PERLROTH, M.D.

Signature: /s/ D. Victor Perloth

Name/Title: D. Victor Perloth

Date: 02/17/2026